159 related articles for article (PubMed ID: 35968590)
21. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
22. A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse.
Yan X; Chen B; Jing H; Yang Z; Zhang T; Lin Y; Shi J
J Hematop; 2023 Dec; 16(4):235-240. PubMed ID: 38175437
[TBL] [Abstract][Full Text] [Related]
23. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
Pina-Oviedo S; Bellamy WT; Gokden M
Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of
Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
[TBL] [Abstract][Full Text] [Related]
25. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
28. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
29. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
30. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
31. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
32. Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.
Bhavsar S; Liu YC; Gibson SE; Moore EM; Swerdlow SH
Am J Surg Pathol; 2022 Jan; 46(1):71-82. PubMed ID: 34392269
[TBL] [Abstract][Full Text] [Related]
33. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
34. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
35. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.
Ikoma H; Miyaoka M; Hiraiwa S; Yukie Kikuti Y; Shiraiwa S; Hara R; Kojima M; Ohmachi K; Ando K; Carreras J; Nakamura N
Pathol Int; 2022 Jun; 72(6):321-331. PubMed ID: 35297566
[TBL] [Abstract][Full Text] [Related]
37. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
38. Ocular adnexal lymphoma: Subtype-specific clinical and genetic features.
Kirkegaard MK
Acta Ophthalmol; 2022 Oct; 100 Suppl 270():3-37. PubMed ID: 36196757
[TBL] [Abstract][Full Text] [Related]
39. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
[TBL] [Abstract][Full Text] [Related]
40. [The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].
Li M; Zhang QL; Zhao W; Huang X; Gong LP; Shi QF; Liu CL; Gao ZF
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):124-128. PubMed ID: 33858042
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]